Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Finasteride

Known as: (5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasterida, 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- 
A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
INTRODUCTION Currently, only topical minoxidil (MNX) and oral finasteride (FNS) are approved by the Food and Drug Administration… Expand
  • figure 1
Highly Cited
2003
Highly Cited
2003
BACKGROUND Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Highly Cited
2003
Highly Cited
2003
BACKGROUND Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 4
Highly Cited
1998
Highly Cited
1998
Background Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the… Expand
Highly Cited
1998
Highly Cited
1998
Contrary to common perceptions, the reliability of quantitative assays for the determination of drugs in biological fluids using… Expand
Highly Cited
1998
Highly Cited
1998
BACKGROUND Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the… Expand
Highly Cited
1996
Highly Cited
1996
BACKGROUND Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic… Expand
Highly Cited
1996
Highly Cited
1996
OBJECTIVES Six randomized clinical trials have compared at least 1 year of 5 mg finasteride to placebo in the treatment of… Expand
Highly Cited
1993
Highly Cited
1993
  • P. Walsh
  • The Journal of urology
  • 1993
  • Corpus ID: 13550733
Background Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate… Expand
Highly Cited
1992
Highly Cited
1992
BACKGROUND Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate… Expand